tbuckley/cabot-search huggingface dataset:
Colorectal cancer (CRC) among very elderly ( &gt; 80 yo) patients (pts): A Brazilian single institution cohort.
Authors: Marcela Crosara Alves Texeira, Kelsen Moura, Pedro Cabral, Suelen Medeiros Silva, Allan Andresson Lima Pereira, Frederico Costa, Jorge Sabagga, Paulo Marcelo Hoff, Gustavo Dos Santos Fernandes
Journal: Journal of Clinical Oncology (2019)

507 Background: Approximately 60% of all cancers and 70% of the mortality occurs in pts aged 65 years and over. Despite that, there is a significant lack of evidence regarding the safety and efficacy of treatments for this part of the population. Our goal is to profile very elderly (VE) pts with gastrintestinal malignancies to highlight research opportunities and improve cancer care among this growing population. Methods: We retrospectively analyzed very elderly pts that attended at Sírio Libanês Hospital in Brazil in a 3 year period and had colorrectal cancer (CRC) diagnosed. We collected information from electronic medical charts on age, gender, ECOG-PS, staging, and surgery. We also gathered information about the type of treatment and survival from diagnosis. Results: Of 88 consecutive VE GI cancer pts, 40 (45,4%) were found to have CRC being 29 colon and 11 rectum. 14 patients were considered to have right sided tumors and 26 left sided. Among CRC pts, the median age was 82, 5 yo and 21 (52.5%) were men. ECOG-PS at diagnosis was 0/1 in 29pts, 19 (47.5%) presented as stage IV disease and 27 pts had surgery of the primary site. As treatment 23(57.5%) received chemotherapy, being 4 adjuvant and 19 palliative. Single agent fluoropyrimidine was the first line therapy in 47%, chemotherapy doublet in 42%, 26% pts received anti-VEGF. Six patients with rectal cancer received chemoRT. The median survival among the stage IV CRC pts was 27.5ms. Conclusions: This cohort is one of the few reported data on VE population cancer, the incidence of cancer in this age group is high and deserve to be more characterized in both trials and retrospective data. Interestingly, those patients seem to benefit from treatments likewise historic data from average age patients. Treatment details, tumor location, pathology, and survival curves will be presented.
A New Personalized, Patient-Centric, and Cost-Conscious Guideline for Contemporary Cholesterol Management
Authors: Eric Peterson, Philip Greenland
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Design strategies and application progress of therapeutic exosomes
Authors: Chunying Liu, Changqing Su
Journal: Theranostics (2019)

Exosomes have great potential to be drug delivery vehicles due to their natural material transportation properties, intrinsic long-term circulatory capability, and excellent biocompatibility, which are suitable for delivering a variety of chemicals, proteins, nucleic acids, and gene therapeutic agents.However, an effective method of loading specific protein agents into exosomes for absorption by target cells is still lacking.The application potential of exosome is still limited.In this review, we discussed the methods for loading specific treating molecules (proteins, nucleic acids and small chemicals) into exosomes, the design strategies for cell and tissue targeting, and the factors for exosome formation.This review can be used as a reference for further research as well as for the development of therapeutic exosomes.
Patient Bone Marrow Chimerism at Time of Donor Lymphocyte Infusion Predicts Development of Graft Versus Host Disease
Authors: Eva AS Koster, Liesbeth C. de Wreede, Sylwia Wallet-Malicka, Lisette Bogers, Peter van Balen, Waf Marijt, Inge Jedema, Peter von dem Borne, Hendrik Veelken, J.H. Frederik Falkenburg, Constantijn J.M. Halkes
Journal: Blood (2018)
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial
Authors: Orly Vardeny, Brian Claggett, Jessica Kachadourian, Akshay S. Desai, Milton Packer, Jean Rouleau, Michael R. Zile, Karl Swedberg, Martin Lefkowitz, Victor Shi, John J.V. McMurray, Scott D. Solomon
Journal: European Journal of Heart Failure (2019)

Aims To assess differences in diuretic dose requirements in patients treated with sacubitril/valsartan compared with enalapril in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM‐HF) trial. Methods and results Overall, 8399 patients with New York Heart Association class II–IV heart failure and reduced LVEF were randomized to sacubitril/valsartan 200 mg bid or enalapril 10 mg twice daily. Loop diuretic doses were assessed at baseline, 6, 12, and 24 months, and furosemide dose equivalents were calculated via multiplication factors (2x for torsemide and 40x for bumetanide). Percentages of participants with reductions or increases in loop diuretic dose were determined. At baseline, 80.8% of participants were taking any diuretics ( n = 6290 for loop diuretics, n = 496 for other diuretics); of those, recorded dosage data for loop diuretics were available on 5487 participants. Mean baseline furosemide equivalent doses were 48.2 mg for sacubitril/valsartan and 49.6 mg for enalapril ( P = 0.25). Patients treated with sacubitril/valsartan were more likely to reduce diuretic dose and less likely to increase diuretic dose relative to those randomized to enalapril at 6, 12, 24 months post‐randomization, with an overall decreased diuretic use of 2.0% ( P = 0.02), 4.1% ( P &lt; 0.001), and 6.1% ( P &lt; 0.001) at 6, 12, and 24 months, respectively, with similar findings in an on‐treatment analysis. Conclusion Treatment with sacubitril/valsartan was associated with more loop diuretic dose reductions and fewer dose increases compared with enalapril, suggesting that treatment with sacubitril/valsartan may reduce the requirement for loop diuretics relative to enalapril in patients with heart failure with reduced ejection fraction.
Abstract 17154: Cardiopulmonary Exercise Testing and Prognosis in HFpEF: the Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) Project
Authors: Clinton A Brawner, Ali Shafiq, Heather A Aldred, Raakesh Hassan, Stephanie Vasko, Matthew A Saval, Jonathan K Ehrman, Yelena Selektor, Christina Tita, Mauricio Valez, Celeste T Williams, David E Lanfear, Steven J Keteyian
Journal: Circulation (2014)

The prognostic utility of cardiopulmonary exercise testing (CPX) in patients with heart failure and reduced ejection fraction (HFrEF) has received much attention. However, there are limited data on the value of CPX in patients with HF and preserved EF (HFpEF). Purpose: Among patients with HFpEF, describe the association between select CPX measures and prognosis for the composite endpoint of mortality, left ventricular assist device (LVAD), or cardiac transplant (CT). Methods: Patients with a CPX between 1997 and 2010 and confirmed HFrEF (EF ≤ 40%; n= 1,201) or HFpEF (EF ≥ 50%; n= 192) were identified. Patients with HFpEF (n= 189, age= 54 ± 14 y, 43% female, EF = 56 ± 5%) were matched (propensity score) to patients with HFrEF (n= 189, age= 54 ± 13 y, 43% female, EF = 22 ± 9%) based on age, gender, history of coronary artery disease, and body mass index. Endpoint data was obtained through 2011. The association between select CPX measures and the endpoint was assessed using Cox regression with adjustment for age, gender, EF, and beta-blocker therapy. Results: There were 53 events (28%; median follow-up = 5.1 y) among the HFpEF group and 88 events (47%; median follow-up = 3.6 y) among the HFrEF group. Results from the Cox regression analyses are shown in the Table. Percent predicted peak VO 2 was one of the best predictors of the endpoint in both HFpEF and HFrEF with similar hazard ratios. Although significantly related to the endpoint among HFrEF, V E -VCO 2 slope and peak P ET CO 2 were not significant among HFpEF. Conclusions: These data support the use of % predicted peak VO 2 to risk stratify patients with HFpEF and suggest that the prognostic utility of some CPX measures developed in HFrEF may not be relevant in HFpEF. Additional research is needed to define the association between CPX measures and prognosis specifically for patients with HFpEF.
Weight Increase during Induction Therapy Predicts Intensive Care Unit (ICU) Transfer in Patients (Pts) with Acute Promyelocytic Leukemia (APL)
Authors: Kamal Chamoun, Hagop M. Kantarjian, Kiran Naqvi, Xuemei Wang, Guillermo Garcia-Manero, Gautam Borthakur, Elias J. Jabbour, Tapan M. Kadia, Naval G. Daver, Courtney D. DiNardo, Nitin Jain, Marina Y. Konopleva, Jorge E. Cortes, Farhad Ravandi, Musa Yilmaz
Journal: Blood (2018)
Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis
Authors: Gary M Hunninghake
Journal: Thorax (2019)

Interstitial lung abnormalities, when present in members of undiagnosed family members recruited on the basis of familial interstitial pneumonia, or in undiagnosed research participants, have been associated with a syndrome that includes distinct sets of imaging abnormalities, restrictive physiological and exercise impairments, and an increased prevalence of histopathological findings, and genetic predictors, that have been noted in patients with idiopathic pulmonary fibrosis. Recent longitudinal studies have demonstrated that qualitative and quantitative assessments of interstitial abnormalities are associated with accelerated lung function decline, an increased rate of clinical diagnoses of interstitial lung disease and an increased rate of mortality. In this perspective, in addition to reviewing the prior information, four major efforts that could help the field of early pulmonary fibrosis detection move forward are discussed. These efforts include: (1) developing standards for characterising and reporting imaging findings from patients with existing CTs; (2) developing consensus statements on when undiagnosed and asymptomatic imaging abnormalities should be considered a disease; (3) identifying populations for which screening efforts might be beneficial; and (4) considering approaches to developing effective secondary prevention trials.
Myocardial Infarction With Nonobstructive Coronary Arteries Assessed by 11C-Acetate Cardiac PET
Authors: Sang-Geon Cho, Yongcheol Kim, Myung Ho Jeong, Hee-Seung Bom
Journal: Clinical Nuclear Medicine (2019)

C-acetate PET can quantify myocardial blood flow and oxidative metabolism (kmono) with a single imaging study. We present a 63-year-old man with myocardial infarction with nonobstructive coronary arteries due to vasospasm, who underwent C-acetate PET after antispastic medication. By quantifying myocardial blood flow and kmono, C-acetate PET could detect the initial ischemic insult by vasospasm and sufficient amount of remaining viable myocardium, while excluding significant inducible ischemia. We suggest that C-acetate PET can be a clinically valuable tool for assessing the pathophysiology of myocardial infarction with nonobstructive coronary arteries.
Abstract 18503: Preliminary Results From the Multicenter International Registry on Electrical Storm Patients: The ELECTRA Study
Authors: Federico Guerra, Paolo Bonelli, Francesca Patani, Claudio Cupido, Laura Cipolletta, Michele Accogli, Corrado Carbucicchio, Valentina Catto, Gaetano M De Ferrari, Gabriele Dell'Era, Veronica Dusi, Oscar Fabregat-Andrés, Eraldo Occhetta, Pietro Palmisano, Alessandro Capucci
Journal: Circulation (2017)

Introduction: Electrical storm (ES) is defined as three or more episodes of ventricular fibrillation (VF) or ventricular tachycardia (VT) within 24 hours and is associated with an increased cardiac...
Abstract 18911: Electrocardiographic Assessment of Brugada Syndrome in Children
Authors: Meena Fatah, Jason Klemensberg, Shayenthiran Sreetharan, Laura Fenwick, Myriam Lafreniere-Roula, Robert Hamilton
Journal: Circulation (2016)

Background: Increasing numbers of children are being referred for assessment of Brugada syndrome (BrS) following the diagnosis of BrS in a parent. We sought to study the ECG phenotype of Brugada syndrome in children referred for assessment. Methods: Subjects were children with a diagnosis of BrS or its mutations, and referred children of adults with a diagnosis of BrS. All standard electrocardiograms (ECGs), modified Brugada lead ECGs, signal-averaged ECGs (SAECGs), and procainamide challenge results were derived from GE Medical ECG systems (MUSE measurement matrix), and compared to a cohort of normal children aged 5 to 15 years. Results: 41 subjects were evaluated. For standard ECG parameters, subjects referred for assessment of BrS more frequently had Q waves absent in V6 and present in AVR. R-wave amplitudes were lower across the precordial leads, and R wave duration was longer in AVR, but with no R’ wave. No differences were found in ST J-point, midpoint or endpoint levels between subjects and control...
Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory WaldenstrÃ¶m Macroglobulinemia Patients
Authors: Giulia Benevolo, Simone Ferrero, Alessandro Andriani, Anna Castiglione, Anna Baraldi, Carola Boccomini, Maria Giuseppina Cabras, Catello Califano, Federica Cavallo, Annarita Conconi, Luigi Curreli, Daniela Drandi, Gianluca Gaidano, Stefano Felici, Martina Ferrante, Donato Mannina, Michele Merli, Anna Lia Molinari, Pellegrino Musto, Gerardo Musuraca, Francesca Gaia Rossi, Roberto Sartori, Monica Tani, Marzia Varettoni, Umberto Vitolo, Lorella Orsucci
Journal: Blood (2018)
O-GlcNAc Transferase Suppresses Inflammation and Necroptosis by Targeting Receptor-Interacting Serine/Threonine-Protein Kinase 3
Authors: Xinghui Li, Wei Gong, Hao Wang, Tianliang Li, Kuldeep S. Attri, Robert E. Lewis, Andre C. Kalil, Fatema Bhinderwala, Robert Powers, Guowei Yin, Laura E. Herring, John M. Asara, Yu L. Lei, Xiaoyong Yang, Diego A. Rodriguez, Mao Yang, Douglas R. Green, Pankaj K. Singh, Haitao Wen
Journal: Immunity (2019)
Comparison of Narrowband UV-B With Psoralen–UV-A Phototherapy for Patients With Early-Stage Mycosis Fungoides
Authors: Kevin Phan, Vignesh Ramachandran, Hiva Fassihi, Deshan F. Sebaratnam
Journal: JAMA Dermatology (2019)

IMPORTANCE Phototherapy is one of the mainstays of treatment for early mycosis fungoides (MF).The most common modalities are psoralen-UV-A (PUVA) and narrowband UV-B (NBUVB).OBJECTIVE To compare the efficacy and adverse effects of PUVA vs NBUVB in early-stage MF.DATA SOURCES A systematic review was performed by searching Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Ovid Medline, PubMed, Cochrane Library, American College of Physicians ACP Journal Club, and Database of Abstracts of Review of Effectiveness from inception to March 30, 2018.UV A, PUVA, mycosis fungoides, Sézary syndrome, cutaneous T-cell lymphoma, UV B, and UVB were used as either key words or MeSH terms.STUDY SELECTION Studies of cohorts with histologically confirmed early-stage MF, defined as stages IA, IB, and IIA, that compared PUVA vs NBUVB, had at least 10 patients in each comparator group, and reported outcomes of response to therapy.Exclusion criteria were studies with patients with stage IIB or higher MF, pediatric patients, fewer than 10 in each comparator group, noncomparative studies, case reports, and abstract studies. DATA EXTRACTION AND SYNTHESISThe Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline was followed.Data were pooled using a random-effects model with odds ratio (OR) as effect size.MAIN OUTCOMES AND MEASURES Main outcomes were complete response rate, partial response rate, disease recurrence, and adverse effects, including erythema, nausea, pruritus, phototoxic effects, dyspepsia, and pain. RESULTSSeven studies were included with a total of 778 patients (405 of 724 [55.9%] men; mean age, 52 years); 527 were treated with PUVA and 251 with NBUVB.Most of the included studies were of poor to moderate quality.Any response was found in 479 of the 527 (90.9%) patients treated with PUVA vs 220 of 251 (87.6%) treated with NBUVB (OR, 1.40; 95% CI, 0.84-2.34;P = .20).Complete response was found in 389 of 527 (73.8%) patients who received PUVA vs 156 of 251 (62.2%) who received NBUVB, which was statistically significant (OR, 1.68; 95% CI, 1.02-2.76;P = .04).Partial response was similar (90 of 501 [18.0%] vs 64 of 233 [27.5%];OR, 0.58; 95% CI, 0.33-1.04;P = .07).No significant difference was found between PUVA and NBUVB in terms of adverse effects of erythema (38 of 527 [7.2%] vs 17 of 251 [6.7%]; P = .54),nausea (10 of 527 [1.9%] vs 3 of 251 [1.2%]; P = .72),pruritus (2 of 527 [0.4%] vs 4 of 251 [1.7%]; P = .26),phototoxic effects (7 of 527 [1.4%] vs 2 of 251 [0.9%]; P = .72),dyspepsia (6 of 527 [1.2%] vs 0 of 251 [0%]; P = .59),or pain (0 of 527 [0%] vs 2 of 251 [0.9%]; P = .50). CONCLUSIONS AND RELEVANCEThe findings suggest that PUVA is a potential alternative to NBUVB in the management of early-stage MF.These findings have implications for clinicians involved in the management of early-stage MF.
Asthma and affective traits in adults: a genetically informative study
Authors: Kelli Lehto, Nancy L. Pedersen, Catarina Almqvist, Yi Lu, Bronwyn K. Brew
Journal: European Respiratory Journal (2019)

Depression, anxiety and high neuroticism (affective traits) are often comorbid with asthma. A causal direction between the affective traits and asthma is difficult to determine; however, there may be a common underlying pathway attributable to shared genetic factors. Our aim was to determine whether a common genetic susceptibility exists for asthma and each of the affective traits. An adult cohort from the Swedish Twin Registry underwent questionnaire-based health assessments (n=23 693) and genotyping (n=15 908). Firstly, questionnaire-based associations between asthma and affective traits were explored. This was followed by genetic analyses: 1) polygenic risk scores (PRS) for affective traits were used as predictors of asthma in the cohort, and 2) genome-wide association results from UK Biobank were used in linkage-disequilibrium score regression (LDSC) to quantify genetic correlations between asthma and affective traits. Analyses found associations between questionnaire-based asthma and affective traits (OR 1.67, 95% CI 1.50–1.86 major depression; OR 1.45, 95% CI 1.30–1.61 anxiety; and OR 1.60, 95% CI 1.40–1.82 high neuroticism). Genetic susceptibility for neuroticism explained the variance in asthma with a dose–response effect; that is, study participants in the highest neuroticism PRS quartile were more likely to have asthma than those in the lowest quartile (OR 1.37, 95% CI 1.17–1.61). Genetic correlations were found between depression and asthma (r g =0.17), but not for anxiety or neuroticism. We conclude that the observed comorbidity between asthma and the affective traits may in part be due to shared genetic influences between asthma and depression (LDSC) and neuroticism (PRS), but not anxiety.
Clinical Impact of an Accurate Genetic Characterization of Older Acute Myeloid Leukemia Patients: A Report from the Northern Italy Leukemia Group (NILG) Randomized Trial 02/06
Authors: Chiara Caprioli, Tamara Intermesoli, Orietta Spinelli, Silvia Salmoiraghi, Pamela Zanghì, Roberta Cavagna, Anna Michelato, Ksenija Buklijas, Federica Delaini, Elena Oldani, Giacomo Gianfaldoni, Dario Ferrero, Elisabetta Terruzzi, Lorella De Paoli, Chiara Cattaneo, Erika Borlenghi, Irene Cavattoni, Monica Tajana, Anna Maria Scattolin, Daniele Giovanni Mattei, Paolo Corradini, Leonardo Campiotti, Fabio Ciceri, Massimo Bernardi, Elisabetta Todisco, Agostino Cortelezzi, Sergio Cortelazzo, Ernesta Audisio, Filippo Marmont, Alberto Bosi, Brunangelo Falini, Chiara Pavoni, Renato Bassan, Alessandro Rambaldi, Federico Lussana
Journal: Blood (2018)
Tendon Tissue Engineering: Effects of Mechanical and Biochemical Stimulation on Stem Cell Alignment on Cell‐Laden Hydrogel Yarns
Authors: Chiara Rinoldi, Marco Costantini, Ewa Kijeńska‐Gawrońska, Stefano Testa, Ersilia Fornetti, Marcin Heljak, Monika Ćwiklińska, Robert Buda, Jacopo Baldi, Stefano Cannata, Jan Guzowski, Cesare Gargioli, Ali Khademhosseini, Wojciech Swieszkowski
Journal: Advanced Healthcare Materials (2019)

Fiber-based approaches hold great promise for tendon tissue engineering enabling the possibility of manufacturing aligned hydrogel filaments that can guide collagen fiber orientation, thereby providing a biomimetic micro-environment for cell attachment, orientation, migration, and proliferation. In this study, a 3D system composed of cell-laden, highly aligned hydrogel yarns is designed and obtained via wet spinning in order to reproduce the morphology and structure of tendon fascicles. A bioink composed of alginate and gelatin methacryloyl (GelMA) is optimized for spinning and loaded with human bone morrow mesenchymal stem cells (hBM-MSCs). The produced scaffolds are subjected to mechanical stretching to recapitulate the strains occurring in native tendon tissue. Stem cell differentiation is promoted by addition of bone morphogenetic protein 12 (BMP-12) in the culture medium. The aligned orientation of the fibers combined with mechanical stimulation results in highly preferential longitudinal cell orientation and demonstrates enhanced collagen type I and III expression. Additionally, the combination of biochemical and mechanical stimulations promotes the expression of specific tenogenic markers, signatures of efficient cell differentiation towards tendon. The obtained results suggest that the proposed 3D cell-laden aligned system can be used for engineering of scaffolds for tendon regeneration.